Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA Breast Cancer Clinical Trials

Vaccine Therapy and Trastuzumab w/wo Polysaccharide-K for Stage IV HER2 Positive Breast Cancer
Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®) Concurrently With a HER2 ICD Peptide-Based Vaccine and Trastuzumab in Patients With Stage IV Breast Cancer
Status Conditions Phase Study ID
Pending HER2-positive Breast Cancer Phase I/II NCT01922921
Summary

This randomized phase I/II trial studies the side effects of vaccine therapy and trastuzumab with or without polysaccharide-K and to see how well it works in treating patients with stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer. Vaccines made from HER2 intracellular domain (ICD) peptide may help the body build an effective immune response to kill tumor cells that express HER2. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumors to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Polysaccharide-K may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether vaccine therapy and trastuzumab is more effective when given with or without polysaccharide-K in treating breast cancer.


Investigator
Lupe G. Salazar, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Patients with stage IV HER2+ breast cancer treated to:
    • No evidence of disease (NED), or
    • Stable bone only disease after definitive therapy
  • HER2 overexpression by immunohistochemistry (IHC) of 2+ or 3+ in the primary tumor or metastasis; or documented gene amplification by fluorescent in situ hybridization (FISH) analysis; IHC =< 2+ must have HER2 gene amplification documented by FISH
  • Patients must continue trastuzumab monotherapy dosing per standard of care through the vaccine portion of the study
  • Patients must be at least 21 days post cytotoxic chemotherapy prior to enrollment
  • Patients must be at least 14 days post systemic steroids prior to enrollment
  • Patients must be at least 28 days from use of any mushroom supplements (examples: turkey tail, reishi, maitake, shiitake) and agree to withhold them for the entire study period (one year)
  • Patients on bisphosphonates and/or endocrine therapy are eligible
  • Men and women of reproductive ability must agree to contraceptive use during entire study period
  • Patients must have Zubrod performance status score of =< 2
  • Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have significant active concurrent medical illnesses precluding study treatment
  • White blood cell (WBC) >= 3000/mm^3
  • Hemoglobin (Hgb) >= 10 mg/dl
  • Serum creatinine =< 2.0 mg/dl or creatinine clearance > 60 ml/min
  • Total bilirubin =< 1.5 mg/dl
  • Serum glutamic oxaloacetic transaminase (SGOT) =< 2.5 times the upper limit of normal
  • Patients must have adequate cardiac function as demonstrated by normal left ventricular ejection fraction (LVEF) on multi gated acquisition (MUGA) scan or echocardiogram performed within 3 months of enrollment
Exclusions (conditions that would prevent participation in this study)
  • Patients with any of the following cardiac conditions:
    • Restrictive cardiomyopathy
    • Unstable angina within 6 months prior to enrollment
    • New York Heart Association functional class III-IV heart failure
    • Symptomatic pericardial effusion
  • Patients with any contraindication to receiving rhu granulocyte macrophage colony stimulating factor (rhuGM-CSF) based products
  • Patients with any clinically significant autoimmune disease requiring active treatment
  • Patients receiving any concurrent immunomodulators
  • Patients who are pregnant or breast-feeding
  • Patients who are simultaneously enrolled in other treatment studies
  • Patients who have received a previous HER2 breast cancer vaccine
  • Known hypersensitivity reaction to mushroom products
Last Updated
October 08, 2013
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.